MedTrace Logo

Endovascular GSN Ablation in Subjects With HFpEF

NCT04287946 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and potential benefits of single-side block of a nerve that connects to the intestines, liver and spleen called the "greater splanchnic nerve" for the treatments of patients with symptomatic heart failure who have normal pumping of the heart. The study will be performed in patients whose heart failure is not responding well to standard treatments and remain symptomatic.

Conditions

Interventions

DEVICE

Ablation

Ablation of a single-side of the greater splanchnic nerve

Sponsors & Collaborators

  • Axon Therapies, Inc.

    lead INDUSTRY

Principal Investigators

  • Howard Levin, MD · Coridea, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2024-06-30
Completion
2024-11-30
FDA Device
Yes

Countries

  • Czechia
  • Georgia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287946 on ClinicalTrials.gov